|
|
Analysis of the Current Status of Global Bispecific Antibody Development |
MAO Kai-yun,LI Rong,LI Dan-dan,ZHAO Ruo-chun,FAN Yue-lei,JIANG Hong-bo() |
Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031,China |
|
|
Abstract The past decade has seen breakthrough progress in bispecific antibody development worldwide, with four products approved for marketing and multiple products entering clinical and preclinical studies. With a unique biological mechanism that distinguishes them from mAbs, dual antibodies hold promise as the next generation of biologic therapies against cancer, autoimmune, and infectious diseases, but the development of dual antibodies is more complex and has higher technical barriers. In this paper, we analyze the global progress in the overall development of dual antibody, the landscape of corporate R & D, and the progress of product R & D in the future, in order to provide references for the choice of direction of dual antibody R & D for related firms and the regional industrial decision.
|
Received: 30 July 2021
Published: 01 December 2021
|
|
Corresponding Authors:
Hong-bo JIANG
E-mail: hbjiang@sibs.ac.cn
|
|
|
[1] |
Nisonoff A, Wissler F C, Lipman L N. Properties of the major component of a peptic digest of rabbit antibody. Science, 1960, 132(3441):1770-1771.
doi: 10.1126/science.132.3441.1770
|
|
|
[2] |
Labrijn A F, Janmaat M L, Reichert J M, et al. Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery, 2019, 18(8):585-608.
doi: 10.1038/s41573-019-0028-1
pmid: 31175342
|
|
|
[3] |
Nie S W, Wang Z Z, Moscoso-Castro M, et al. Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antibody Therapeutics, 2020, 3(1):18-62.
doi: 10.1093/abt/tbaa003
|
|
|
[4] |
Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Molecular Cancer Therapeutics, 2020, 19(10):2044-2056.
doi: 10.1158/1535-7163.MCT-20-0071
|
|
|
[5] |
Jovčevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs, 2020, 34(1):11-26.
doi: 10.1007/s40259-019-00392-z
pmid: 31686399
|
|
|
[6] |
Hussain R M, O’Leary P, Eichenbaum D A, et al. Faricimab. Anti-Ang-2/anti-VEGF-A bispecific antibody, Treatment of diabetic macular edema, Treatment of wet age-related macular degeneration. Drugs of the Future, 2020, 45(7):449.
doi: 10.1358/dof.2020.45.7.3127028
|
|
|
[7] |
van der Horst H J, de Jonge A V, Hiemstra I H, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer Journal, 2021, 11:38.
doi: 10.1038/s41408-021-00430-6
|
|
|
[8] |
Patriarca A, Gaidano G. Investigational drugs for the treatment of diffuse large B-cell lymphoma. Expert Opinion on Investigational Drugs, 2021, 30(1):25-38.
doi: 10.1080/13543784.2021.1855140
pmid: 33295827
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|